- Population : Immunocompetent children aged 9–24 months
- Intervention: Single-dose MenA conjugate vaccine (5 µg dosage)
- Comparison: No MenA vaccination
- Outcome : Serogroup A meningococcal disease
What is the scientific evidence concerning the efficacy of a single dose of MenA conjugate vaccine (versus no Men A vaccination) against serogroup A meningococcal disease in immunocompetent children aged 9–24 months?
- GRADE table
- Meningococcal disease